Skip to main content
Erschienen in: Journal of Neurology 12/2020

16.07.2020 | Original Communication

Prodromal Parkinson disease in patients with idiopathic hyposmia

verfasst von: Paula Marrero-González, Alex Iranzo, David Bedoya, Mònica Serradell, Aida Niñerola-Baizán, Andrés Perissinotti, Carles Gaig, Isabel Vilaseca, Isam Alobid, Joan Santamaría, Joaquim Mullol

Erschienen in: Journal of Neurology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Idiopathic hyposmia (IH) is a prodromal marker of Parkinson disease (PD). However, IH is common in the general population and only a minority will develop PD. Identification of individuals with IH at prodromal stage of PD would serve to select them to implement neuroprotective agents, when available.

Objective

To identify prodromal PD in IH patients using the Movement Disorders Society (MDS) research criteria for prodromal PD.

Methods

We applied the MDS research criteria for prodromal PD to 25 consecutive patients older than 50 years who were self-referred for smell loss and had IH, and to 18 controls. A number of risk and prodromal PD markers were assessed in all participants including REM sleep behavior disorder (RBD) by video-polysomnography and nigrostriatal dopaminergic dysfunction by DAT-SPECT. After follow-up of 4.7 ± 2.2 years, participants were re-assessed to look for incident PD.

Results

Prodromal PD probability was higher in patients than in controls (19.45 ± 34.9% versus 1.74 ± 4.48%; p = 0.019). Four (16%) patients met the criteria of prodromal PD surpassing 80% probability (99.8%, 99.5%, 88.3%, 86.4%). Three (12%) patients had RBD and four (16%) abnormal DAT-SPECT. At the end of follow-up, one (4%) IH patient who had RBD and baseline prodromal PD probability of 86.4% developed PD, while all controls remained disease free.

Conclusions

Prodromal PD is infrequent among IH patients. MDS research criteria for prodromal PD are useful to identify a subgroup of IH patients at high risk of PD when RBD is assessed by video-polysomnography and nigrostriatal dopamine deficiency with DAT-SPECT.
Literatur
1.
Zurück zum Zitat de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535PubMed de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535PubMed
2.
Zurück zum Zitat de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general study: The Rotterdam Study. Neurology 63:1204–1244 de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general study: The Rotterdam Study. Neurology 63:1204–1244
3.
Zurück zum Zitat Postuma RB, Berg D, Stern M, Poewe W, Marek K, Litvan I (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1599PubMed Postuma RB, Berg D, Stern M, Poewe W, Marek K, Litvan I (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1599PubMed
4.
Zurück zum Zitat Mahlknecht P, Seppi K, Poewe W (2015) The concept of prodromal Parkinson’s disease. J Parkinsons Dis 5:681–697PubMedPubMedCentral Mahlknecht P, Seppi K, Poewe W (2015) The concept of prodromal Parkinson’s disease. J Parkinsons Dis 5:681–697PubMedPubMedCentral
5.
Zurück zum Zitat Noyce AJ, Lees AJ, Schrag AE (2016) The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:871–878PubMed Noyce AJ, Lees AJ, Schrag AE (2016) The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:871–878PubMed
6.
Zurück zum Zitat Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12:622–634PubMed Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12:622–634PubMed
7.
Zurück zum Zitat Ward CD, Hess WA, Calne DB (1983) Olfactory impairment in Parkinson’s disease. Neurology 33:943–946PubMed Ward CD, Hess WA, Calne DB (1983) Olfactory impairment in Parkinson’s disease. Neurology 33:943–946PubMed
8.
Zurück zum Zitat Hawkes C (2003) Olfaction in neurodegenerative disorder. Mov Disord 18:364–372PubMed Hawkes C (2003) Olfaction in neurodegenerative disorder. Mov Disord 18:364–372PubMed
9.
Zurück zum Zitat Tissingh G, Berendese HW, Bergmans P et al (2011) Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 16:41–46 Tissingh G, Berendese HW, Bergmans P et al (2011) Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 16:41–46
10.
Zurück zum Zitat Pont-Sunyer C, Hotter A, Gaig C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PD Study). Mov Disord Mov Disord 30:229–237PubMed Pont-Sunyer C, Hotter A, Gaig C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PD Study). Mov Disord Mov Disord 30:229–237PubMed
11.
Zurück zum Zitat Marin C, Vilas D, Langdon C et al (2018) Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep 18(8):42PubMed Marin C, Vilas D, Langdon C et al (2018) Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep 18(8):42PubMed
13.
Zurück zum Zitat Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842PubMed Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842PubMed
14.
Zurück zum Zitat Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 67:167–173 Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 67:167–173
15.
Zurück zum Zitat Jennings D, Siderowf A, Stern M et al (2017) Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol 74:933–940PubMedPubMedCentral Jennings D, Siderowf A, Stern M et al (2017) Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol 74:933–940PubMedPubMedCentral
16.
Zurück zum Zitat Noyce AJ, R’Bibo L, Peress L et al (2017) PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson’s disease. Mov Disord 32:219–226PubMedPubMedCentral Noyce AJ, R’Bibo L, Peress L et al (2017) PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson’s disease. Mov Disord 32:219–226PubMedPubMedCentral
17.
Zurück zum Zitat Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY (2011) Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69:811–818PubMed Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY (2011) Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69:811–818PubMed
18.
Zurück zum Zitat Mahlknecht P, Iranzo A, Högl B et al (2015) Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84:654–658PubMed Mahlknecht P, Iranzo A, Högl B et al (2015) Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84:654–658PubMed
19.
Zurück zum Zitat Ponsen MM, Stoffers D, Booji J, van Eck-Smit BLF, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181PubMed Ponsen MM, Stoffers D, Booji J, van Eck-Smit BLF, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181PubMed
20.
Zurück zum Zitat Murphy C, Schubert CR, Cruickshanks KJ, Klein BEK, Klein R, Nondhal DM (2002) Prevalence of olfactory impairment in older adults. JAMA 288:2307–2312PubMed Murphy C, Schubert CR, Cruickshanks KJ, Klein BEK, Klein R, Nondhal DM (2002) Prevalence of olfactory impairment in older adults. JAMA 288:2307–2312PubMed
21.
Zurück zum Zitat Mullol J, Alobid I, Mariño-Sánchez F et al (2012) Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open 2:e001256PubMedPubMedCentral Mullol J, Alobid I, Mariño-Sánchez F et al (2012) Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open 2:e001256PubMedPubMedCentral
22.
Zurück zum Zitat Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the parkinson at-risk syndrome study. Mov Disord 27:406–412PubMedPubMedCentral Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the parkinson at-risk syndrome study. Mov Disord 27:406–412PubMedPubMedCentral
23.
Zurück zum Zitat Haehner A, Masala C, Walter S, Reichmann H, Hummel T (2019) Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss. J Neurol 266:339–345PubMed Haehner A, Masala C, Walter S, Reichmann H, Hummel T (2019) Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss. J Neurol 266:339–345PubMed
24.
Zurück zum Zitat Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1609PubMed Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1609PubMed
25.
Zurück zum Zitat Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34:1464–1470PubMed Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34:1464–1470PubMed
26.
Zurück zum Zitat Mahlknecht P, Gasperi A, Djamshidian A et al (2018) Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: a population-based 10-year study. Mov Disord 33:405–413PubMed Mahlknecht P, Gasperi A, Djamshidian A et al (2018) Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: a population-based 10-year study. Mov Disord 33:405–413PubMed
27.
Zurück zum Zitat Pilotto A, Heinzel S, Suenkel U et al (2017) Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord 32:1025–1034PubMed Pilotto A, Heinzel S, Suenkel U et al (2017) Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord 32:1025–1034PubMed
28.
Zurück zum Zitat Iranzo A, Stefani A, Serradell M et al (2017) Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 89:242–248PubMed Iranzo A, Stefani A, Serradell M et al (2017) Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 89:242–248PubMed
29.
Zurück zum Zitat Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB (2017) Validation of the MDS research criteria for prodromal Parkinson’s disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord 32:865–873PubMed Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB (2017) Validation of the MDS research criteria for prodromal Parkinson’s disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord 32:865–873PubMed
30.
Zurück zum Zitat Skorvanek M, Ladomirjakova Z, Han V et al (2017) Prevalence of prodromal Parkinson’s disease as defined by MDS research criteria among elderly patients undergoing colonoscopy. J Parkinsons Dis 7:481–489PubMed Skorvanek M, Ladomirjakova Z, Han V et al (2017) Prevalence of prodromal Parkinson’s disease as defined by MDS research criteria among elderly patients undergoing colonoscopy. J Parkinsons Dis 7:481–489PubMed
31.
Zurück zum Zitat Mirelman A, Saunders-Pullman R, Alcalay RN et al (2018) Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers. Mov Disord 33:966–973PubMedPubMedCentral Mirelman A, Saunders-Pullman R, Alcalay RN et al (2018) Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers. Mov Disord 33:966–973PubMedPubMedCentral
32.
Zurück zum Zitat Cardesin A, Alobid I, Benitez P et al (2006) Barcelona Smell Test-24 (BAST-24): validation and smell characteristics in the healthy Spanish population. Rhinology 44:83–89PubMed Cardesin A, Alobid I, Benitez P et al (2006) Barcelona Smell Test-24 (BAST-24): validation and smell characteristics in the healthy Spanish population. Rhinology 44:83–89PubMed
33.
Zurück zum Zitat American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Darien American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Darien
34.
Zurück zum Zitat Frauscher B, Iranzo A, Gaig C et al (2012) Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep 35:835–847PubMedPubMedCentral Frauscher B, Iranzo A, Gaig C et al (2012) Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep 35:835–847PubMedPubMedCentral
35.
Zurück zum Zitat Iranzo A, Santamaría J, Valldeoriola F et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82:419–428PubMed Iranzo A, Santamaría J, Valldeoriola F et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82:419–428PubMed
36.
Zurück zum Zitat Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170PubMed Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170PubMed
37.
Zurück zum Zitat Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72PubMed Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72PubMed
38.
Zurück zum Zitat Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMed Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMed
39.
Zurück zum Zitat Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMed
40.
Zurück zum Zitat Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMed Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMed
41.
Zurück zum Zitat Delgado C, Araneda A, Behrens MI (2019) Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years. Neurologia 34(6):376–385PubMed Delgado C, Araneda A, Behrens MI (2019) Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years. Neurologia 34(6):376–385PubMed
42.
Zurück zum Zitat American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, Washington American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, Washington
43.
Zurück zum Zitat Doty RL (1995) The smell identification test administration manual, 3rd edn. Sensonics, Philadelphia Doty RL (1995) The smell identification test administration manual, 3rd edn. Sensonics, Philadelphia
44.
Zurück zum Zitat Mahlknecht P, Gasperi A, Willeit P et al (2016) Prodromal Parkinson’s disease as defined per MDS research criteria in the general elderly community. Mov Disord 31:1405–1408PubMed Mahlknecht P, Gasperi A, Willeit P et al (2016) Prodromal Parkinson’s disease as defined per MDS research criteria in the general elderly community. Mov Disord 31:1405–1408PubMed
45.
Zurück zum Zitat Iranzo A, Santamaria J, Tolosa E (2016) Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol 15:405–419PubMed Iranzo A, Santamaria J, Tolosa E (2016) Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol 15:405–419PubMed
46.
Zurück zum Zitat Pujol M, Pujol J, Alonso T et al (2017) Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography. Sleep Med 40:116–121PubMed Pujol M, Pujol J, Alonso T et al (2017) Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography. Sleep Med 40:116–121PubMed
47.
Zurück zum Zitat Iranzo A, Fernández-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in Idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 9(2):e89741PubMedPubMedCentral Iranzo A, Fernández-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in Idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 9(2):e89741PubMedPubMedCentral
48.
Zurück zum Zitat Weil RS, Morris HR (2019) REM sleep behaviour disorder: an early window for prevention in neurodegeneration? Brain 142:498–501PubMedPubMedCentral Weil RS, Morris HR (2019) REM sleep behaviour disorder: an early window for prevention in neurodegeneration? Brain 142:498–501PubMedPubMedCentral
49.
Zurück zum Zitat Fantini ML, Postuma RB, Montplaisir J, Ferini-Strambi L (2006) Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 70:386–390PubMed Fantini ML, Postuma RB, Montplaisir J, Ferini-Strambi L (2006) Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 70:386–390PubMed
50.
Zurück zum Zitat Iranzo A, Serradell M, Vilaseca I et al (2013) Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 19:600–604PubMed Iranzo A, Serradell M, Vilaseca I et al (2013) Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 19:600–604PubMed
51.
Zurück zum Zitat Jennings D, Siderowf A, Stern M et al (2014) Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 83:1739–1746PubMedPubMedCentral Jennings D, Siderowf A, Stern M et al (2014) Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 83:1739–1746PubMedPubMedCentral
52.
Zurück zum Zitat Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426PubMed Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426PubMed
53.
Zurück zum Zitat Booji J, Tissingh G, Boer GJ et al (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140 Booji J, Tissingh G, Boer GJ et al (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140
54.
Zurück zum Zitat Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301PubMed Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301PubMed
55.
Zurück zum Zitat Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with [123I]-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698PubMed Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with [123I]-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698PubMed
56.
Zurück zum Zitat Iranzo A, Valldeoriola F, Lomeña F et al (2011) Progressive nigrostriatal dopaminergic dysfunction in idiopathic REM sleep behavior disorder: a prospective study. Lancet Neurol 10:797–805PubMed Iranzo A, Valldeoriola F, Lomeña F et al (2011) Progressive nigrostriatal dopaminergic dysfunction in idiopathic REM sleep behavior disorder: a prospective study. Lancet Neurol 10:797–805PubMed
57.
Zurück zum Zitat Erro R, Picillo M, Vitale C et al (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17PubMed Erro R, Picillo M, Vitale C et al (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17PubMed
58.
Zurück zum Zitat Khoo TK, Yarnall AJ, Duncan GW et al (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281PubMedPubMedCentral Khoo TK, Yarnall AJ, Duncan GW et al (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281PubMedPubMedCentral
59.
Zurück zum Zitat Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMed Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMed
60.
Zurück zum Zitat Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 26:653–658PubMedPubMedCentral Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 26:653–658PubMedPubMedCentral
61.
Zurück zum Zitat Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64PubMed Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64PubMed
Metadaten
Titel
Prodromal Parkinson disease in patients with idiopathic hyposmia
verfasst von
Paula Marrero-González
Alex Iranzo
David Bedoya
Mònica Serradell
Aida Niñerola-Baizán
Andrés Perissinotti
Carles Gaig
Isabel Vilaseca
Isam Alobid
Joan Santamaría
Joaquim Mullol
Publikationsdatum
16.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-10048-6

Weitere Artikel der Ausgabe 12/2020

Journal of Neurology 12/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.